Innovative Genomics Institute

Innovative Genomics Institute
Name	Innovative Genomics Institute
Established	2014
Type	Research institute
Location	Berkeley, California
Director	Jennifer Doudna
Affiliations	University of California, Berkeley; Gladstone Institutes; Lawrence Berkeley National Laboratory

Innovative Genomics Institute is a research institute founded to accelerate genome engineering and translational science. The institute connects laboratory research, clinical translation, and public policy through collaborations among universities, institutes, foundations, and companies. It mobilizes cross-disciplinary teams to advance genome-editing technologies, field-deployable diagnostics, and equitable access to biotechnology.

History

The institute emerged from efforts at the University of California, Berkeley and the Gladstone Institutes after landmark discoveries in CRISPR biology and genome editing by researchers associated with University of California, Berkeley, Harvard University, Massachusetts Institute of Technology, Broad Institute, University of California, San Francisco, and Howard Hughes Medical Institute. Early organizational milestones involved partnerships with Lawrence Berkeley National Laboratory, Chan Zuckerberg Initiative, Gordon and Betty Moore Foundation, Bill & Melinda Gates Foundation, and the establishment of translational pathways with UCSF Medical Center, Stanford University School of Medicine, and Salk Institute for Biological Studies. Founding leadership included scientists affiliated with Jennifer Doudna, Emmanuelle Charpentier, Feng Zhang, and advisors from National Institutes of Health, National Academy of Sciences, and Howard Hughes Medical Institute. Over time the institute engaged with initiatives like Precision Medicine Initiative, Global Alliance for Genomics and Health, and public dialogues tied to events such as the Asilomar Conference on Recombinant DNA and the World Health Organization consultations on human genome editing.

Mission and Research Focus

The institute’s mission emphasizes translating discoveries in genome engineering into tools for human health, agriculture, and conservation while engaging bioethics and policy debates led by bodies such as the National Academy of Medicine, Presidential Commission for the Study of Bioethical Issues, European Commission, United Nations Environment Programme, and World Health Organization. Research focuses integrate CRISPR systems characterized in studies from Max Planck Institute for Infection Biology, Pasteur Institute, Cold Spring Harbor Laboratory, Yale University School of Medicine, Johns Hopkins University, and University of Cambridge to develop diagnostics inspired by platforms from Mammoth Biosciences, SHERLOCK (CRISPR), and STOPCovid. The institute also pursues projects with agricultural partners like International Rice Research Institute, CIMMYT, and conservation groups connected to WWF and IUCN.

Organizational Structure and Affiliations

The institute is organized into research cores, translational units, policy and ethics teams, and education outreach groups collaborating with University of California, Berkeley, Gladstone Institutes, Lawrence Berkeley National Laboratory, UC San Francisco, Stanford University, and biotech companies such as Intellia Therapeutics, Editas Medicine, CRISPR Therapeutics, Caribou Biosciences, and Synthego. Governance includes advisory input from leaders at National Institutes of Health, Howard Hughes Medical Institute, Bill & Melinda Gates Foundation, Chan Zuckerberg Initiative, and academic bodies like American Association for the Advancement of Science and Biophysical Society. Educational affiliations include partnerships with Berkeley Lab Summer Undergraduate Research Program, NIH postdoctoral training, and community engagement via Science Museum of Virginia-style public programs and collaborations with local organizations such as City of Berkeley cultural institutions.

Key Research Programs and Projects

Major programs span therapeutic genome editing, portable diagnostics, plant genome engineering, and conservation genomics. Therapeutic pipelines reference preclinical methods from labs at Broad Institute, Massachusetts General Hospital, Scripps Research, and Mayo Clinic and engage clinical partners like UCSF Medical Center and UCSF Benioff Children’s Hospital. Diagnostic efforts build on CRISPR diagnostics pioneered in projects related to Mammoth Biosciences, Zika virus response teams, Ebola virus outbreak diagnostics, and collaborations with Centers for Disease Control and Prevention and World Health Organization rapid-response programs. Agricultural initiatives collaborate with International Maize and Wheat Improvement Center (CIMMYT), International Rice Research Institute, and USDA Agricultural Research Service to adapt genome-editing methods used in studies at John Innes Centre and Rothamsted Research. Conservation projects align with efforts by IUCN, Conservation International, and The Nature Conservancy addressing invasive species and endangered populations, using genomic approaches similar to research at WCS (Wildlife Conservation Society) and Smithsonian Institution.

Facilities and Technology Platforms

Core facilities include high-throughput sequencing suites, single-cell genomics platforms, cryo-electron microscopy resources, and plant growth and containment greenhouses mirroring infrastructure at Lawrence Berkeley National Laboratory, Berkeley Lab Molecular Foundry, EMBL-EBI, Wellcome Sanger Institute, and Broad Institute. Technology platforms support CRISPR enzymes discovery, base editing, prime editing, and diagnostics leveraging technologies developed at Max Planck Institute for Biochemistry, Cold Spring Harbor Laboratory, Salk Institute, Friedrich Miescher Institute, and commercial platforms from Illumina, Oxford Nanopore Technologies, and Thermo Fisher Scientific. Computational genomics and AI partnerships involve groups at Google DeepMind, IBM Research, Stanford AI Lab, and UC Berkeley AI Research (BAIR).

Ethics, Policy, and Public Engagement

Ethics and policy activities convene stakeholders from National Academy of Sciences, National Academy of Medicine, World Health Organization, Nuffield Council on Bioethics, European Group on Ethics, and advocacy organizations including OpenAI, Electronic Frontier Foundation, AAAS programs, and community groups. Public engagement includes forums modeled after the Asilomar Conference on Recombinant DNA, town halls with local governments like City of Berkeley, educational collaborations with Lawrence Hall of Science, and curricular initiatives with California Department of Education-aligned programs. Policy scholarship draws on legal and ethical analyses from Harvard Law School, Stanford Law School, Yale Law School, Georgetown University, and think tanks such as Brookings Institution and RAND Corporation.

Funding and Partnerships

Funding sources and partnerships combine philanthropic donors like Chan Zuckerberg Initiative, Bill & Melinda Gates Foundation, Moore Foundation, and public agencies including National Institutes of Health, National Science Foundation, California Institute for Regenerative Medicine, and Department of Energy. Industry collaborations include alliances with Intellia Therapeutics, CRISPR Therapeutics, Editas Medicine, Mammoth Biosciences, and Ginkgo Bioworks. International partnerships encompass European Commission Horizon 2020, Wellcome Trust, UK Research and Innovation, and organizations such as World Health Organization and Food and Agriculture Organization of the United Nations to support translational projects and global access initiatives.

Category:Research institutes Category:Genetics